Passage BIO, Inc.
Close on Oct 19, 2026
- Market cap
- $11.49M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | Before market open | – | $4.09 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | – | $-2.44 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.25 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | Before market open | – | $-0.20 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | $-0.31 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.26 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 4, 2024 | Before market open | – | $-0.30 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | Before market open | – | $-0.49 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | Before market open | – | $-0.44 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | Before market open | – | $-0.63 | – |
Press releases
Announcements Passage BIO filed with the SEC
Passage Bio and Remix Therapeutics Announce
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CONFIDENTIAL Modulating RNA Processing TO TARGET THE UNDRUGGABLE Investor Presentation June 2026
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PASSAGE BIO REPORTS UPDATED INTERIM DATA FROM
Regulation FD disclosure · EX-99.1 to Form 8-K
© 2026 Passage Bio. All rights reserved.
Regulation FD disclosure · EX-99.2 to Form 8-K
PASSAGE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2026 Passage Bio. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
© 2026 Passage Bio. All rights reserved. Corporate Presentation Redefining the Course of Neurodegenerative Conditions January 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PASSAGE BIO REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PASSAGE BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio Announces 1-for-20 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
UPDATED INTERIM DATA FROM UPLIFT-D STUDY AND PROVIDES PROGRAM UPDATE
Other events · EX-99.1 to Form 8-K
PASSAGE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PASSAGE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PASSAGE BIO ANNOUNCES INTERIM DATA FROM UPLIFT-D
Results of operations · Exit or restructuring costs · Material impairment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PASSAGE BIO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31 st Annual Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Non-clinical and early clinical development of PBFT02,
Regulation FD disclosure · EX-99.2 to Form 8-K
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Interim Safety and Biomarker Data From upliFT-D Trial
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
PASSAGE BIO REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD- C9orf72 Patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PASSAGE BIO REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PASSAGE BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2023 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones, including the progress of
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones, including the progress of
Regulation FD disclosure · EX-99.1 to Form 8-K
OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
PASSAGE BIO ANNOUNCES PROMISING INITIAL DATA
Other events · EX-99.1 to Form 8-K
PASSAGE BIO REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our the progress of clinical trials and
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K